Skip to main content

Aptevo Therapeutics Inc 8-K, filed Oct 26, 2026

Aptevo Therapeutics Inc. (APVO)

8-K 2026-10-26 For: 2026-10-26
View Original
Added on October 26, 2026

About this 8-K

Aptevo Therapeutics Inc filed this 8-K on October 26, 2026.

Aptevo said ten of 47 (21%) evaluable frontline AML patients treated with mipletamig plus venetoclax and azacitidine advanced to allogeneic stem cell transplant. Nine came from the ongoing RAINIER trial and one from a completed dose expansion trial. AI summary

Items reported

  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits